Cargando…

Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease

Isosorbide-2-carbamates-5-aryl esters are highly potent and very selective butyrylcholinesterase inhibitors. The objective of the present work was to address the hypothesis that the isosorbide-aryl-5-ester group could be replaced with an antioxidant functionality while maintaining inhibitor effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Mike, Wang, Jun, Harmon, Shona, Kling, Beata, Heilmann, Jörg, Gilmer, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273432/
https://www.ncbi.nlm.nih.gov/pubmed/27534722
http://dx.doi.org/10.3390/molecules21040440
_version_ 1783377383189905408
author Jones, Mike
Wang, Jun
Harmon, Shona
Kling, Beata
Heilmann, Jörg
Gilmer, John F.
author_facet Jones, Mike
Wang, Jun
Harmon, Shona
Kling, Beata
Heilmann, Jörg
Gilmer, John F.
author_sort Jones, Mike
collection PubMed
description Isosorbide-2-carbamates-5-aryl esters are highly potent and very selective butyrylcholinesterase inhibitors. The objective of the present work was to address the hypothesis that the isosorbide-aryl-5-ester group could be replaced with an antioxidant functionality while maintaining inhibitor effects and selectivity. We successfully incorporated ferulic acid or lipoic acid groups producing potent selective inhibitors of butyrylcholinesterase (BuChE). The hybrid compounds were non-toxic to the murine hippocampal cell line HT-22 and lipoate esters were neuroprotective at 10 and 25 µM when the cells were challenged with glutamate (5 mM) in a similar manner to the positive control quercetin. The benzyl carbamate 7a was a potent inhibitor of BuChE (IC(50) 150 nM) and it was effective in reducing glutamate toxicity to neuronal cells at >5 µM. Representative compounds exhibited an antioxidant effect in the oxygen radical absorbance capacity assay as the lipoate 7d was not active, whereas the ferulate 8a showed a weak, but significant, activity with 0.635 ± 0.020 Trolox Equivalent.
format Online
Article
Text
id pubmed-6273432
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62734322018-12-28 Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease Jones, Mike Wang, Jun Harmon, Shona Kling, Beata Heilmann, Jörg Gilmer, John F. Molecules Communication Isosorbide-2-carbamates-5-aryl esters are highly potent and very selective butyrylcholinesterase inhibitors. The objective of the present work was to address the hypothesis that the isosorbide-aryl-5-ester group could be replaced with an antioxidant functionality while maintaining inhibitor effects and selectivity. We successfully incorporated ferulic acid or lipoic acid groups producing potent selective inhibitors of butyrylcholinesterase (BuChE). The hybrid compounds were non-toxic to the murine hippocampal cell line HT-22 and lipoate esters were neuroprotective at 10 and 25 µM when the cells were challenged with glutamate (5 mM) in a similar manner to the positive control quercetin. The benzyl carbamate 7a was a potent inhibitor of BuChE (IC(50) 150 nM) and it was effective in reducing glutamate toxicity to neuronal cells at >5 µM. Representative compounds exhibited an antioxidant effect in the oxygen radical absorbance capacity assay as the lipoate 7d was not active, whereas the ferulate 8a showed a weak, but significant, activity with 0.635 ± 0.020 Trolox Equivalent. MDPI 2016-04-01 /pmc/articles/PMC6273432/ /pubmed/27534722 http://dx.doi.org/10.3390/molecules21040440 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Jones, Mike
Wang, Jun
Harmon, Shona
Kling, Beata
Heilmann, Jörg
Gilmer, John F.
Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title_full Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title_fullStr Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title_full_unstemmed Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title_short Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer’s Disease
title_sort novel selective butyrylcholinesterase inhibitors incorporating antioxidant functionalities as potential bimodal therapeutics for alzheimer’s disease
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273432/
https://www.ncbi.nlm.nih.gov/pubmed/27534722
http://dx.doi.org/10.3390/molecules21040440
work_keys_str_mv AT jonesmike novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease
AT wangjun novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease
AT harmonshona novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease
AT klingbeata novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease
AT heilmannjorg novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease
AT gilmerjohnf novelselectivebutyrylcholinesteraseinhibitorsincorporatingantioxidantfunctionalitiesaspotentialbimodaltherapeuticsforalzheimersdisease